Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in locally advanced or metastatic NSCLC (B-F1RST)
NCT02848651Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2016
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Started Sep 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02848651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848651.